Parmax Pharma 2026 Open Offer: Price, Dates, Control

What has been disclosed

Parmax Pharma Limited has disclosed two linked corporate developments that investors are tracking closely. One is a board meeting scheduled for Friday, August 14, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026. The second is a change-in-control transaction that has triggered a mandatory open offer to public shareholders.

The open offer is linked to a substantial share acquisition via a Share Purchase Agreement (SPA) and a proposed preferential issue. The disclosures identify Dhiren Chandulal Shah and Sunil Chinubhai Shah as the acquirers, along with persons acting in concert (PACs). The company has described the overall transaction as a change in control at Parmax Pharma.

Board meeting on August 14 for June-quarter results

The company has scheduled its board of directors meeting on Friday, August 14, 2026. The stated agenda is to consider and approve unaudited standalone financial results for the quarter ended June 30, 2026. Beyond the timing and purpose of the meeting, the disclosure provided here does not include additional financial numbers for the quarter.

The meeting date matters because it lands soon after the open offer tendering window described in the offer schedule. Investors typically watch results timelines closely during control transitions because any corporate updates can influence shareholder attention and decision-making.

Open offer at ₹42.80 per share and its size

Parmax Pharma’s shares are subject to an open offer priced at ₹42.80 per share. The open offer size is up to 23,46,250 fully paid-up equity shares, representing 26.00% of the company’s expanded voting share capital. The maximum consideration, assuming full acceptance, is stated at ₹10.04 crore.

The escrow amount disclosed for the offer is ₹5.20 crore, deposited in an escrow account with ICICI Bank. The disclosures also state that the escrow exceeds the 25% regulatory requirement.

Why the open offer was triggered

The disclosure links the open offer trigger to a substantial share acquisition through a Share Purchase Agreement and a proposed preferential issue. The transaction is described as resulting in a change in control at Parmax Pharma.

The open offer is being made under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosures reference Regulations 3(1) and 4 for the mandatory offer requirement. A separate filing was made to BSE under Regulation 18(6) of the same regulations.

Off-market acquisition at ₹35 and the jump in holding

A consortium led by Dhiren Chandulal Shah and Sunil Chinubhai Shah acquired 11,52,450 shares of Parmax Pharma for ₹35 per share on August 13, 2026. The acquisition is described as an off-market deal governed by a Share Purchase Agreement executed in June.

After this purchase, the group’s holding increased from 27.20% to 58.01%, giving it majority control. The disclosures also describe the purchase as being carried out by Dhiren Chandulal Shah, Sunil Chinubhai Shah, and eight other PACs.

Preferential issue and warrants mentioned in the offer materials

The offer materials also reference a proposed preferential issue to the acquirers and PACs. The disclosed structure includes 22,80,444 equity shares and 17,16,574 warrants at ₹36.50 per share or warrant.

Separately, the disclosures state that the acquirers are also acquiring 11,52,450 equity shares, representing 12.77% of expanded voting capital, from existing promoters or sellers at ₹35.00 per share under the SPA.

Key dates and process disclosed for shareholders

The open offer is described as commencing on July 30, 2026, with tendering closing on August 12, 2026. Another disclosure also mentions that from July 29, 2026, public shareholders can tender shares, with the offer remaining open until August 12, 2026.

Payments are scheduled by August 27, 2026, followed by a final announcement by September 3, 2026. The “Identified Date” for determining eligible shareholders is stated as Thursday, July 16, 2026.

Offer price versus the cited market price

The offer price is ₹42.80 per share, and one of the disclosures compares this to a market price of ₹102.83. The difference is a factual point noted in the disclosure, and it is relevant because shareholders typically compare the tender price with prevailing market levels when deciding whether to participate.

The offer is also described as not being conditional upon any minimum level of acceptance. That means the offer proceeds irrespective of how many shares are tendered, as per the disclosed terms.

Post-offer shareholding and public float impact

The disclosures state that, post-offer, the acquirer group will hold 94.34% of the company. This implies that public shareholding would reduce to 5.66% on the expanded capital basis if the open offer is fully accepted.

The same disclosed table shows that existing promoters would move from 30.80% pre-offer to 0.00% post-offer, while acquirers and PACs would move from 27.20% pre-offer to 94.34% post-offer. The acquirers and PACs are also expected to be classified as promoters after the transaction.

The disclosures add that the acquirers and PACs have no intention to delist Parmax Pharma. If public shareholding falls below the required minimum of 25%, they have undertaken to take steps to comply within 12 months.

Intermediaries and regulatory filings named in disclosures

Fedex Securities Private Limited is named as the manager to the offer. Purva Sharegistry (India) Private Limited is named as the registrar.

The BSE filing for the acquisition disclosure is stated to have been submitted by Sunil Chinubhai Shah under Regulation 18(6). The filing also notes that all entities involved had been previously disclosed in the Detailed Public Statement dated June 15, 2026, and the Letter of Offer dated July 21, 2026.

Snapshot table: disclosed offer terms and transaction points

Timeline table: the disclosed schedule around the offer

Market impact: what the disclosures indicate

The disclosures point to a sharp shift in control, first through the off-market acquisition that lifted the acquirer group to 58.01%, and then through the open offer that targets up to 26% of the expanded capital. If the open offer is fully accepted, the disclosed post-offer structure reduces public shareholding to 5.66%.

The offer price of ₹42.80 is also contrasted with a cited market price of ₹102.83, highlighting a wide gap. The documents further show that the overall transaction includes a preferential issue of shares and warrants at ₹36.50, alongside the SPA purchase price of ₹35 for the off-market acquisition.

Why this matters: control transition with compliance commitments

The disclosures consistently frame the transaction as a change in control, with Dhiren Chandulal Shah and Sunil Chinubhai Shah named as acquirers along with PACs. The filings also show the transaction is being executed within the SEBI SAST framework, with intermediary appointments, escrow funding, and a defined schedule.

The explicit statement that there is no intent to delist, and the undertaking to restore minimum public shareholding within 12 months if it falls below 25%, sets out the compliance posture disclosed by the acquirers.

Conclusion

Parmax Pharma’s disclosures tie together a results board meeting on August 14, 2026, and a change-in-control transaction involving an SPA, a preferential issue, and a mandatory open offer for 26% of expanded voting capital at ₹42.80 per share. The key near-term events already disclosed include the close of tendering on August 12, the board meeting on August 14, and the scheduled payment and announcement dates that follow the offer timeline.